

<Dendrite Japan News Release>

World Top 40 Pharmaceutical Companies 2005

The following table is the world top 40 pharmaceutical companies researched and made by Dendrite Japan. 'Pharmaceutical' includes prescription drug(Rx), vaccine, contrast agents and does not include OTC, animal health and nutritional products. But some companies with asterisk (*) may include OTC or diagnostic test drugs because they do not disclose the details of their sales. The number like 03/06 after company name means the end of its fiscal year. The fiscal year of the companies without such numbers ends December 31 each year.

(In the past this data was used in the 'Pharmaceutical Industry Vision in Japan' made by Japan's Ministry of Health, Welfare and Labor. Major newspapers in Japan sometimes use this data.)

World Top 40 Pharmaceutical Companies				US\$ mil		US\$ bil	US\$ mil	US\$ mil
05Rank	04Rank	Company	Country	05 Sales	Evol.	R&D	Total Sales	04 Sales
1	1	Pfizer	U.S.	44,284	-4.0%	7.44	51,298	46,133
2	2	Sanofi-Aventis	France	32,350	8.4%	4.79	32,350	34,680
3	3	Glaxo SmithKline	U.K.	32,112	9.1%	5.40	37,273	32,945
4	6	Novartis	Switzerland	24,956	15.8%	4.85	32,212	21,542
5	7	AstraZeneca	U.K.	23,303	11.7%	3.38	23,950	20,866
6	5	Johnson & Johnson	U.S.	22,322	0.9%	3.66	50,514	22,128
7	4	Merck	U.S.	22,012	-4.0%	3.85	22,012	22,939
8	8	Roche	Switzerland	20,729	25.7%	3.79	26,995	19,176
9	10	Wyeth	U.S.	15,321	9.7%	2.75	18,756	13,964
10	9	Bristol-Myers Squibb	U.S.	15,254	-1.5%	2.75	19,207	15,482
11	11	Eli Lilly	U.S.	13,782	5.5%	3.03	14,654	13,059
12	12	Abbott Laboratories	U.S.	13,302	14.8%	1.82	22,338	11,589
13	13	Amgen	U.S.	12,430	17.8%	2.31	12,430	10,550
14	15	Boehringer Ingelheim	Germany	9,233	26.1%	1.56	10,867	8,436
15	14	Takeda Pharmaceutical 03/06	Japan	8,648	11.4%	1.44	10,287	8,877
16	19	Schering-Plough	U.S.	7,564	17.9%	1.87	9,508	6,417
17	16	Astellas Pharma 03/06	Japan	7,195	1.9%	1.21	7,418	8,073
18	24	Genentech	U.S.	6,633	43.5%	1.26	6,633	4,621
19	18	Schering AG	Germany	6,176	8.1%	1.16	6,287	6,579
20	17	Daiichi Sankyo 03/06	Japan	6,118	3.2%	1.31	7,852	6,782
21	21	Novo Nordisk	Denmark	5,351	16.3%	0.81	5,351	5,327
22	23	Teva Pharmaceutical Industries	Israel	5,227	9.4%	0.38	5,250	4,777
23	22	Eisai* 03/06	Japan	4,920	13.5%	0.79	5,103	4,959
24	20	Bayer	Germany	4,817	-7.3%	1.13	32,435	5,987
25	25	Merck KGaA	Germany	4,168	13.5%	0.68	6,953	4,231
26	26	Otsuka Pharm. 03/06	Japan	4,127	12.0%	0.88	6,391	4,213
27	27	Baxter International	U.S.	4,023	7.6%	0.53	9,849	3,739
28	29	TAP Pharmaceutical Products	U.S.	3,260	-3.0%	0.22	3,260	3,362
29	28	Servier	France	3,257	10.9%	0.81	3,257	3,384
30	31	Forest Laboratories 03/06	U.S.	2,912	-6.5%	0.41	2,962	3,114
31	30	Akzo Nobel (Organon)	Netherland	2,872	2.1%	0.52	15,399	3,242
32	33	Chugai Pharm.	Japan	2,776	17.5%	0.42	2,669	2,703
33	38	UCB* (Incl. Celltech)	Belgium	2,773	39.4%	0.60	2,773	2,291
34	37	Solvay (Incl. Fournier)	Belgium	2,689	30.1%	0.42	10,142	2,381
35	32	Altana	Germany	2,646	12.0%	0.50	3,876	2,721
36	34	Menarini*	Italy	2,645	19.5%	NA	2,645	2,550
37	36	Serono	Switzerland	2,586	5.2%	0.59	2,586	2,458
38	39	Biogen Idec	U.S.	2,423	9.5%	0.75	2,423	2,212
39	63	Merck/Schering-Plough Pharm.	U.S.	2,408	103.2%	NA	2,408	1,185
40	43	Genzyme	U.S.	2,388	25.1%	0.50	2,735	1,909
Total Sales of the above				411,992	2.6%			401,580

© K.Nagae/Dendrite Japan

The sales is converted to US dollars at the rate of 12/31/2005 for 2005 sales and at that of 12/31/2004 for 2004 sales. Then the percentage of development (Evolution in the table) does not match the sales in US dollars when the currency of the company is not US dollars.

TAP Pharmaceutical Products ranked 28th is the joint venture of Takeda in Japan and Abbott in the US. The sales of those two companies does not include this sales so TAP is in the top 40. The same for Merck/Schering-Plough Pharmaceuticals ranked 39th.

The next table is the ranking after announced M&A's were completed.

Pharmaceutical Sales Ranking 2005 after M&A's					US\$ bil	US\$ mil
05Rank	Company	Country	05 Sales	Evol.	R&D	04 Sales
1	Pfizer	U.S.	44,284	-4.0%	7.44	46,133
2	Sanofi-Aventis	France	32,350	8.4%	4.79	34,680
3	Glaxo SmithKline	U.K.	32,112	9.1%	5.40	32,945
4	Novartis + Chiron	Switzerland	26,390	15.6%	5.28	22,822
5	AstraZeneca	U.K.	23,303	11.7%	3.38	20,866
6	Johnson & Johnson	U.S.	22,322	0.9%	3.66	22,128
7	Merck	U.S.	22,012	-4.0%	3.85	22,939
8	Roche	Switzerland	20,729	25.7%	3.79	19,176
9	Wyeth	U.S.	15,321	9.7%	2.75	13,964
10	Bristol-Myers Squibb	U.S.	15,254	-1.5%	2.75	15,482
11	Eli Lilly	U.S.	13,782	5.5%	3.03	13,059
12	Abbott Laboratories	U.S.	13,302	14.8%	1.82	11,589
13	Amgen	U.S.	12,430	17.8%	2.31	10,550
14	Bayer + Schering	Germany	10,993	0.7%	2.29	12,566
15	Boehringer Ingelheim	Germany	9,233	26.1%	1.56	8,436
16	Takeda Pharmaceutical 03/06	Japan	8,648	11.4%	1.44	8,877
17	Schering-Plough	U.S.	7,564	17.9%	1.87	6,417
18	Teva Pharm. + Ivax	Israel	7,552	14.2%	0.52	6,614
19	Astellas Pharma 03/06	Japan	7,195	1.9%	1.21	8,113
20	Genentech	U.S.	6,633	43.5%	1.26	4,621
21	Daiichi Sankyo 03/06	Japan	6,118	3.2%	1.31	7,325
22	Novo Nordisk	Denmark	5,351	16.3%	0.81	5,327
23	Eisai* 03/06	Japan	4,920	9.1%	0.75	4,959
24	Merck KGaA	Germany	4,168	13.5%	0.68	4,231

© K.Nagae/Dendrite Japan

Contact: Kentaro Nagae, Dendrite Japan in Osaka
Please e-mail to ubinternational-jp@dendrite.com

Dendrite Japan Corporation
Head Office
Fuso Doshomachi Bldg 9F, 1-7-10 Doshomachi, Chuo-ku, Osaka 541-0045 Japan
Fax 06-6202-7786

When you want to use this data, please write '*Source: Dendrite Japan*' and please send a copy of the writing to the above address or send data including PDF file to the e-mail address above.